Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Rubius Therapeutics, Inc. (RUBY)

0.1693   -0.015 (-7.89%) 12-07 16:00
Open: 0.1723 Pre. Close: 0.1838
High: 0.189 Low: 0.1615
Volume: 408,552 Market Cap: 15(M)

Technical analysis

as of: 2022-12-07 4:25:42 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.32     One year: 0.41
Support: Support1: 0.16    Support2: 0.13
Resistance: Resistance1: 0.28    Resistance2: 0.35
Pivot: 0.21
Moving Average: MA(5): 0.19     MA(20): 0.22
MA(100): 0.52     MA(250): 2.77
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 2.9     %D(3): 4.2
RSI: RSI(14): 27
52-week: High: 13.48  Low: 0.16
Average Vol(K): 3-Month: 1,318 (K)  10-Days: 369 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ RUBY ] has closed above bottom band by 2.9%. Bollinger Bands are 64.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 43 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.19 - 0.19 0.19 - 0.19
Low: 0.16 - 0.16 0.16 - 0.16
Close: 0.17 - 0.17 0.17 - 0.17

Company Description

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 07 Dec 2022
Tar Heel Traveler: Aunt Ruby's Peanuts are "best peanuts in the world" - WRAL News

Wed, 07 Dec 2022
How Ruby & Hart Became Atom & Dot -- & A… - New Haven Independent

Wed, 07 Dec 2022
On top of Ruby Mountain - The Star - The Star of Grand Coulee

Wed, 07 Dec 2022
Judge Rejects Protections For Ruby Pipeline Stalking Horse - Law360

Wed, 07 Dec 2022
Cincinnati restaurateur Jeff Ruby to be honored with street renaming - The Cincinnati Enquirer

Wed, 07 Dec 2022
Ruby Falls And Treetop Hideaways Open Luxury Treehouse Retreat On Lookout Mountain - Chattanooga Pulse

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 90 (M)
Shares Float 46 (M)
% Held by Insiders 5.5 (%)
% Held by Institutions 76.5 (%)
Shares Short 2,180 (K)
Shares Short P.Month 2,990 (K)

Stock Financials

EPS -2.3
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.4
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -42.1
Return on Equity (ttm) -164.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.88
Qtrly Earnings Growth 0
Operating Cash Flow -155 (M)
Levered Free Cash Flow -86 (M)

Stock Valuations

PE Ratio -0.08
PEG Ratio 0
Price to Book value 0.41
Price to Sales 0
Price to Cash Flow -0.1

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.